Understanding The Mechanisms Of Action Of The ISCOMATRIX Adjuvant For The Development Of Human Vaccines
Funder
National Health and Medical Research Council
Funding Amount
$401,361.00
Summary
CSL Limited, an Australian owned global biopharmaceutical company, is developing the ISCOMATRIX (IMX) adjuvant for vaccines to prevent and treat serious human disease of global concern (e.g. cancer, pandemic flu, HPV, HCV). This study will identify the mechanisms of action of IMX in generating strong cellular immunity, how to enhance it further by combining with other immuno-modulators so as to develop novel IMX vaccines for the treatment of established cancer and persistent viral infections.
Dendritic Cells In Innate Immunity And Their Potential Clinical Manipulation
Funder
National Health and Medical Research Council
Funding Amount
$443,946.00
Summary
Dendritic cells (DC) are rare cells that are crucial in response to infection and surveillance of damaged tissues. We aim to understand the tools that are expressed by DC that allow them to sense pathogens and the functions of different DC types once a pathogen has been detected. The ultimate aim is to be able to understand and harness the functions of different DC so that we may directly target them upon demand to aid in the course of infection or potentially as tumour therapy.